Skip to main content

Advertisement

SpringerLink
Log in

Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials

  • Treatment as Prevention (E Geng, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

A Correction to this article was published on 30 June 2020

This article has been updated

Abstract

Purpose of Review

In 2018–2019, studies were published assessing the effectiveness of reducing HIV incidence by expanding HIV testing, linkage to HIV treatment, and assistance to persons living with HIV to adhere to their medications (the “90-90-90” strategy). These tests of “treatment as prevention” (TasP) had complex results.

Recent Findings

The TasP/ANRS 12249 study in South Africa, the SEARCH study in Kenya and Uganda, and one comparison (arms A to C) of the HPTN 071 (PopART) study in South Africa and Zambia did not demonstrate a community impact on HIV incidence. In contrast, the Botswana Ya Tsie study and the second comparison (arms B to C) of PopART indicated significant ≈ 30% reductions in HIV incidence in the intervention communities where TasP was expanded.

Summary

We discuss the results of these trials and outline future research and challenges. These include the efficient expansion of widespread HIV testing, better linkage to care, and viral suppression among all persons living with HIV. A top implementation science priority for the next decade is to determine what strategies to use in specific local contexts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 30 June 2020

    The original version of this review article unfortunately contained a mistake in the category section. The Section Editor was inadvertently captured as ���E Geng��� instead of ���SH Vermund���.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Granich R, Williams B, Montaner J, Zuniga JM. 90-90-90 and ending AIDS: necessary and feasible. Lancet. 2017;390(10092):341–3.

    PubMed  Google Scholar 

  2. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380–2.

    PubMed  CAS  Google Scholar 

  3. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization. 2016.

  4. The Kaiser Family Foundation (KFF). The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR): Kaiser Family Foundation. 2019 [cited 2019 December]. Available from: https://www.kff.org/global-health-policy/fact-sheet/the-u-s-presidents-emergency-plan-for/. Accessed Nov 2019.

  5. Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE. Defining control of HIV epidemics. Lancet HIV. 2018;5(11):e667–e70.

    PubMed  Google Scholar 

  6. Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS Med. 2018;15(10):e1002678.

    PubMed  PubMed Central  Google Scholar 

  7. Sabapathy K, Hensen B, Varsaneux O, Floyd S, Fidler S, Hayes R. The cascade of care following community-based detection of HIV in sub-Saharan Africa–a systematic review with 90-90-90 targets in sight. PLoS One. 2018;13(7):e0200737.

    PubMed  PubMed Central  Google Scholar 

  8. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.

    PubMed  Google Scholar 

  9. Brault MA, Spiegelman D, Hargreaves J, Nash D, Vermund SH. Treatment as prevention: concepts and challenges for reducing HIV incidence. J Acquir Immune Defic Syndr. 2019;82(2):S104.

    PubMed  PubMed Central  Google Scholar 

  10. •• Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018;5(3):e116–e25 This paper presents the primary results and progress towards 90-90-90 of the TasP/ANRS 12249 trial in Kwa-Zulu Natal, South Africa.

    PubMed  Google Scholar 

  11. •• Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, et al. HIV testing and treatment with the use of a community health approach in rural Africa. N Engl J Med. 2019;381(3):219–29 This paper presents the primary HIV and NCD findings from the SEARCH TasP trial conducted in rural Kenya and Uganda.

    PubMed  PubMed Central  Google Scholar 

  12. •• Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med. 2019;381(3):230–42 This paper presents the primary findings related to achievement of 90–90-90 in the BotswanaYa TsieTasP trial.

    PubMed  PubMed Central  Google Scholar 

  13. •• Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al. Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART). N Engl J Med. 2019;381(3):207–18 This study presents the primary findings from the 3 arms of the PopART TasP trial conducted in South Africa and Zambia.

    PubMed  PubMed Central  Google Scholar 

  14. • Perriat D, Balzer L, Hayes R, Lockman S, Walsh F, Ayles H, et al. Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa. J Int AIDS Soc. 2018;21(1):e25048. This paper provides a comparative assessment of the trial designs for the key TasP studies discussed in this review.

  15. • Abdool Karim SS. HIV-1 epidemic control - insights from test-and-treat trials. N Engl J Med. 2019;381(3):286–8 This piece serves as a companion to the three TasP studies published in theNew England Journal of Medicine(SEARCH,Ya Tsie, and PopART), and discusses hypotheses for the mixed findings.

    PubMed  Google Scholar 

  16. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (treatment as prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14:230.

    PubMed  PubMed Central  Google Scholar 

  17. Iwuji CC, Orne-Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, et al. Uptake of home-based HIV testing, linkage to care, and community attitudes about ART in rural KwaZulu-Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster-randomised trial. PLoS Med. 2016;13(8):e1002107.

    PubMed  PubMed Central  Google Scholar 

  18. Plazy M, Farouki KE, Iwuji C, Okesola N, Orne-Gliemann J, Larmarange J, et al. Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa. J Int AIDS Soc. 2016;19(1):20913.

    PubMed  PubMed Central  Google Scholar 

  19. Gosset A, Protopopescu C, Larmarange J, Orne-Gliemann J, McGrath N, Pillay D, et al. Retention in care trajectories of HIV-positive individuals participating in a universal test-and-treat program in rural South Africa (ANRS 12249 TasP trial). J Acquir Immune Defic Syndr. 2019;80(4):375–85.

    PubMed  PubMed Central  Google Scholar 

  20. Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016;3(3):e111–9.

    PubMed  PubMed Central  Google Scholar 

  21. Kwarisiima D, Kamya MR, Owaraganise A, Mwangwa F, Byonanebye DM, Ayieko J, et al. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya. J Int AIDS Soc. 2017;20(Suppl 4):21673.

    PubMed  PubMed Central  Google Scholar 

  22. Camlin CS, Akullian A, Neilands TB, Getahun M, Eyul P, Maeri I, et al. Population mobility associated with higher risk sexual behaviour in eastern African communities participating in a Universal Testing and Treatment trial. J Int AIDS Soc. 2018;21(Suppl 4):e25115.

    PubMed  PubMed Central  Google Scholar 

  23. Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, et al. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017;4(3):e122–e33.

    PubMed  Google Scholar 

  24. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016;3(5):e221–30.

    PubMed  PubMed Central  Google Scholar 

  25. Kebaabetswe P, Manyake K, Kadima E, Auletta-Young C, Chakalisa U, Sekoto T, et al. Barriers and facilitators to linkage to care and ART initiation in the setting of high ART coverage in Botswana. AIDS Care. 2019. https://doi.org/10.1080/09540121.2019.1640843.

  26. Moyo S, Gaseitsiwe S, Mohammed T, Pretorius Holme M, Wang R, Kotokwe KP, et al. Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015. PLoS One. 2018;13(10):e0204840.

    PubMed  PubMed Central  Google Scholar 

  27. Marukutira T, Stoove M, Lockman S, Mills LA, Gaolathe T, Lebelonyane R, et al. A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and Australia. J Int AIDS Soc. 2018;21(3):e25090.

  28. Lasry A, Bachanas P, Suraratdecha C, Alwano MG, Behel S, Pals S, et al. Cost of community-based HIV testing activities to reach saturation in Botswana. AIDS Behav. 2019;23(4):875–82.

    PubMed  PubMed Central  Google Scholar 

  29. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57.

    PubMed  PubMed Central  Google Scholar 

  30. Bock P, Phiri C, Piwowar-Manning E, Kosloff B, Mandla N, Young A, et al. Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. J Int AIDS Soc. 2017;20(Suppl 6):21780.

    PubMed  PubMed Central  Google Scholar 

  31. Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, et al. A universal testing and treatment intervention to improve HIV control: one-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Med. 2017;14(5):e1002292.

    PubMed  PubMed Central  Google Scholar 

  32. Shanaube K, Schaap A, Floyd S, Phiri M, Griffith S, Chaila J, et al. What works - reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in Zambia. AIDS. 2017;31(11):1555–64.

    PubMed  PubMed Central  Google Scholar 

  33. Sabapathy K, Mubekapi-Musadaidzwa C, Mulubwa C, Schaap A, Hoddinott G, Stangl A, et al. Predictors of timely linkage-to-ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case-control study. J Int AIDS Soc. 2017;20(4):e25037.

  34. Iwuji C, Newell ML. Towards control of the global HIV epidemic: addressing the middle-90 challenge in the UNAIDS 90-90-90 target. PLoS Med. 2017;14(5):e1002293.

    PubMed  PubMed Central  Google Scholar 

  35. Bowman AS, Mehta M, Lerebours Nadal L, Halpern M, Nicholas SW, Amesty S. Strengthening the HIV care continuum in the Dominican Republic: application of a triadic implementation framework to meet the UNAIDS 90-90-90 treatment goal. AIDS Patient Care STDs. 2017;31(10):407–12.

    PubMed  Google Scholar 

  36. Wechsberg WM, Ndirangu JW, Speizer IS, Zule WA, Gumula W, Peasant C, et al. An implementation science protocol of the Women’s Health CoOp in healthcare settings in Cape Town, South Africa: a stepped-wedge design. BMC Womens Health. 2017;17(1):85.

    PubMed  PubMed Central  Google Scholar 

  37. Dorward J, Garrett N, Quame-Amaglo J, Samsunder N, Ngobese H, Ngomane N, et al. Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study. BMJ Open. 2017;7(9):e017507.

    PubMed  PubMed Central  Google Scholar 

  38. Gamble T, Branson B, Donnell D, Hall HI, King G, Cutler B, et al. Design of the HPTN 065 (TLC-Plus) study: a study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States. Clin Trials. 2017;14(4):322–32.

    PubMed  PubMed Central  Google Scholar 

  39. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2013;382(9899):1195–203.

    PubMed  Google Scholar 

  40. Meloni ST, Agbaji O, Chang CA, Agaba P, Imade G, Oguche S, et al. The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial. BMC Infect Dis. 2019;19(1):368.

    PubMed  PubMed Central  Google Scholar 

  41. Walsh FJ, Barnighausen T, Delva W, Fleming Y, Khumalo G, Lejeune CL, et al. Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland’s public sector health system: study protocol for a stepped-wedge randomized trial. Trials. 2017;18(1):383.

    PubMed  PubMed Central  Google Scholar 

  42. Kerrigan D, Mbwambo J, Likindikoki S, Beckham S, Mwampashi A, Shembilu C, et al. Project Shikamana: baseline findings from a community empowerment–based combination HIV prevention trial among female sex workers in Iringa, Tanzania. J Acquir Immune Defic Syndr. 2017;74:S60–S8.

    PubMed  Google Scholar 

  43. •• Kerrigan DL, Mbwambo JK, Likindikoki S, et al. Project Shikamana: a community empowerment model of combination prevention significantly impacts HIV incidence and care continuum outcomes among female sex workers in Iringa, Tanzania. J Acquir Immune Defic Syndr. 2019;18(2):141–8 This paper presents the primary findings from the Project Shikamana study implementing TasP with female sex workers in Tanzania.

    Google Scholar 

  44. •• Cowan FM, Davey C, Fearon E, Mushati P, Dirawo J, Chabata S, et al. Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial. Lancet HIV. 2018;5(8):e417–e26 This paper presents the primary findings from the SAPPH-Ire study implementing TasP with female sex workers in Zimbabwe.

    PubMed  Google Scholar 

  45. Mlambo CK, Vernooij E, Geut R, Vrolings E, Shongwe B, Jiwan S, et al. Experiences from a community advisory Board in the Implementation of early access to ART for all in Eswatini: a qualitative study. BMC Med Ethics. 2019;20(1):50.

    PubMed  PubMed Central  Google Scholar 

  46. Pell C, Vernooij E, Masilela N, Simelane N, Shabalala F, Reis R. False starts in ‘test and start’: a qualitative study of reasons for delayed antiretroviral therapy in Swaziland. Int Health. 2018;10(2):78–83.

    PubMed  Google Scholar 

  47. Shabalala FS, Vernooij E, Pell C, Simelane N, Masilela N, Spiegelman D, et al. Understanding reasons for discontinued antiretroviral treatment among clients in test and treat: a qualitative study in Swaziland. J Int AIDS Soc. 2018;21(S4):e25120.

    PubMed  PubMed Central  Google Scholar 

  48. Dlamini-Simelane T, Moyer E. Task shifting or shifting care practices? The impact of task shifting on patients’ experiences and health care arrangements in Swaziland. BMC Health Serv Res. 2017;17(1):20.

    PubMed  PubMed Central  Google Scholar 

  49. Khan S, Spiegelman D, Walsh F, et al. Universal test and treat (UTT) versus standard of care for access to antiretroviral therapy in HIV clients: the MaxART stepped-wedge randomized controlled health systems trial in Swaziland. Paper presented at: The International AIDS Society. 2018; Amsterdam, Netherlands.

  50. Hendrickson ZM, Leddy AM, Galai N, Mbwambo JK, Likindikoki S, Kerrigan DL. Work-related mobility and experiences of gender-based violence among female sex workers in Iringa, Tanzania: a cross-sectional analysis of baseline data from Project Shikamana. BMJ Open. 2018;8(9):e022621.

    PubMed  PubMed Central  Google Scholar 

  51. Leddy AM, Mantsios A, Davis W, Muraleetharan O, Shembilu C, Mwampashi A, et al. Essential elements of a community empowerment approach to HIV prevention among female sex workers engaged in project Shikamana in Iringa, Tanzania. Cult Health Sex. 2019. https://doi.org/10.1080/13691058.2019.1659999.

  52. Busza J, Chiyaka T, Musemburi S, Fearon E, Davey C, Chabata S, et al. Enhancing national prevention and treatment services for sex workers in Zimbabwe: a process evaluation of the SAPPH-IRe trial. Health Policy Plan. 2019;34(5):337–45.

    PubMed  Google Scholar 

  53. Larmarange J. The edges of key populations: how to think, desribe and reach these hidden groups? AIDS impact; 07/30/2019; London, England.

  54. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial. JAMA. 2018;319(11):1103–12.

    PubMed  PubMed Central  Google Scholar 

  55. Hargreaves JR, Krishnaratne S, Mathema H, Lilleston PS, Sievwright K, Mandla N, et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and south African communities: analysis of data from the HPTN071 (PopART) study. AIDS. 2018;32(6):783–93.

    PubMed  PubMed Central  Google Scholar 

  56. Seeley J, Bond V, Yang B, Floyd S, MacLeod D, Viljoen L, et al. Understanding the time needed to link to care and start ART in seven HPTN 071 (PopART) study communities in Zambia and South Africa. AIDS Behav. 2019;23(4):929–46.

    PubMed  Google Scholar 

  57. Bond V, Nomsenge S, Mwamba M, Ziba D, Birch A, Mubekapi-Musadaidzwa C, et al. “Being seen” at the clinic: Zambian and South African health worker reflections on the relationship between health facility spatial organisation and items and HIV stigma in 21 health facilities, the HPTN 071 (PopART) study. Health Place. 2019;55:87–99.

    PubMed  PubMed Central  Google Scholar 

  58. McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat Med. 2018;24(4):491–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  59. Granich R, Williams BG. Treatment as prevention trials and ending AIDS: what do we know, when did we know it, and what do we do now? Curr Opin HIV AIDS. 2019;14(6):514–20.

    PubMed  Google Scholar 

  60. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511.

    PubMed  PubMed Central  Google Scholar 

  61. Estill J, Marsh K, Autenrieth C, Ford N. How to achieve the global 90-90-90 target by 2020 in sub-Saharan Africa? A mathematical modelling study. Tropical Med Int Health. 2018;23(11):1223–30.

    Google Scholar 

  62. Fauci AS, Eisinger RW. PEPFAR - 15 years and counting the lives saved. N Engl J Med. 2018;378(4):314–6.

    PubMed  Google Scholar 

  63. Goosby E, Von Zinkernagel D, Holmes C, Haroz D, Walsh T. Raising the bar: PEPFAR and new paradigms for global health. J Acquir Immune Defic Syndr. 2012;60(Suppl 3):S158–62.

    PubMed  Google Scholar 

  64. Heaton LM, Bouey PD, Fu J, Stover J, Fowler TB, Lyerla R, et al. Estimating the impact of the US President’s emergency plan for AIDS relief on HIV treatment and prevention programmes in Africa. Sex Transm Infect. 2015;91(8):615–20.

    PubMed  Google Scholar 

  65. Sturchio JL, Cohen GM. How PEPFAR’s public-private partnerships achieved ambitious goals, from improving labs to strengthening supply chains. Health Aff (Millwood). 2012;31(7):1450–8.

    Google Scholar 

  66. Webster P. PEPFAR at 15 years. Lancet. 2018;392(10143):200.

    PubMed  Google Scholar 

Download references

Funding

The authors of this study are supported by National Institutes of Health grants K12HS023000 (MAB), R01AI112339 (DS, SHV), P30MH062294 (MAB, SHV), and UM1AI068619 (SHV).

Author information

Authors and Affiliations

  1. Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT, USA

    Marie A. Brault

  2. Department of Biostatistics; Center for Methods in Implementation and Prevention Sciences, Yale School of Public Health, New Haven, CT, USA

    Donna Spiegelman

  3. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA

    Salim S. Abdool Karim

  4. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

    Sten H. Vermund

Authors
  1. Marie A. Brault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna Spiegelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salim S. Abdool Karim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sten H. Vermund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie A. Brault.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Treatment as Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brault, M.A., Spiegelman, D., Abdool Karim, S.S. et al. Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Curr HIV/AIDS Rep 17, 249–258 (2020). https://doi.org/10.1007/s11904-020-00492-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-020-00492-4

Keywords

Search

Navigation